Free tool
FAERS Monitor: Oseni
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022426 or its brand name (Oseni, Alogliptin Benzoate, Pioglitazone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
249
Serious
67
27% of reports
Hospitalization
36
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- weight increased21
- drug ineffective11
- fatigue11
- rash11
- blood glucose increased10
- pancreatitis10
- headache9
- vision blurred9
- arthralgia8
- myalgia8
- nausea8
- abdominal pain upper7
- pain7
- joint swelling6
- oedema6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 63 |
| 2015 | 103 |
| 2016 | 32 |
| 2017 | 13 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,910 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancreatitisSignal | 10 | 16.0 | 8.7 | 126 |
| oedemaSignal | 6 | 9.3 | 4.2 | 37 |
| weight increasedSignal | 21 | 7.9 | 5.3 | 121 |
| vision blurredSignal | 9 | 5.5 | 2.9 | 29 |
| blood glucose increasedSignal | 10 | 4.5 | 2.4 | 24 |
| joint swellingSignal | 6 | 4.2 | 1.9 | 12 |
| myalgiaSignal | 8 | 4.0 | 2.0 | 15 |
| abdominal pain upperSignal | 7 | 2.9 | 1.4 | 7 |
| rashSignal | 11 | 2.1 | 1.2 | 6 |
| arthralgia | 8 | 1.6 | 0.8 | 1 |
| headache | 9 | 1.2 | 0.6 | 0 |
| fatigue | 11 | 1.2 | 0.7 | 0 |
| pain | 7 | 1.0 | 0.5 | 0 |
| nausea | 8 | 0.9 | 0.4 | 0 |
| drug ineffective | 11 | 0.7 | 0.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.